Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data

Michael R. McClung(Bone Health and Osteoporosis Foundation), P. D. Delmas(Inserm), David E. Burgio(Procter & Gamble (United States)), Christian Roux(Hôpital Pasteur), S. Boonen(KU Leuven), José Zanchetta(Universidad del Salvador), John F. Beary(Procter & Gamble (United States)), Artur Racewicz, Z. Man(Merck & Co., Inc., Rahway, NJ, USA (United States)), Claude Laurent Benhamou(Inserm), Ellen Matzkin(Sanofi (United States)), Rachelle Eusebio(Procter & Gamble (United States))
Osteoporosis International
June 29, 2012
10.1007/s00198-012-2056-0
Cited by 31

Related Papers

Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2001|4.6k
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2009|3.5k
Romosozumab in Postmenopausal Women with Low Bone Mineral Density
|New England Journal of Medicine|2014|1.2k
Efficacy of Bazedoxifene in Reducing New Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis: Results From a 3-Year, Randomized, Placebo-, and Active-Controlled Clinical Trial
|Journal of Bone and Mineral Research|2008|508
Effects of teriparatide versus alendronate for treating glucocorticoid‐induced osteoporosis: Thirty‐six–month results of a randomized, double‐blind, controlled trial
|Arthritis & Rheumatism|2009|497